The history of Viagra presents a complex picture for investors. While the initial release generated massive returns, the end of its patent opened the floodgates to off-brand alternatives, dramatically eroding market share. This presents a particular challenge for pharmaceutical companies banking on related blockbuster medications, suggesting that a

The story of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, yielding billions in revenue , its patent expiration created a wave of lower-priced alternatives , significantly impacting its market share . While certain firms may seek to capitalize on related treatments , the current